L Zhang1, Q Meng2, S Chen3, M Zhang2, B Chen2, B Wu2, G Yan4, X Wang5, Z Jia6. 1. Department of Epidemiology and Biostatistics, School of Public Health, Peking University, Beijing, PR China; National Institute of Drug Dependence, Peking University, Beijing, PR China. 2. Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, PR China. 3. Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, PR China. Electronic address: shchen@cdc.zj.cn. 4. School of Computer Science, University of Nottingham, Nottingham, United Kingdom. 5. Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, Zhejiang, PR China. Electronic address: xmwang@cdc.zj.cn. 6. National Institute of Drug Dependence, Peking University, Beijing, PR China. Electronic address: urchinjj@163.com.
Abstract
OBJECTIVES: To examine treatment outcomes and factors associated with poor outcome of multidrug-resistant (MDR) tuberculosis (TB) in China. METHODS: We conducted a prospective observational cohort study including consecutive patients with MDR-TB between 2009 and 2013 in six regions of Zhejiang province. Patients were prescribed treatments by infectious disease specialists, and treatment outcomes were recorded. Sociodemographic characteristics were obtained through a structured questionnaire. The primary endpoint was poor treatment outcomes, defined as treatment failure based on microbiologic persistence, default (lost to follow-up) or death at 24 months. We assessed risk factors for poor treatment outcomes using a Cox proportional hazards model. RESULTS: A total of 820 MDR-TB patients were observed, and 537 with known treatment outcomes were included in our study. Overall, the treatment success rate was 40.2 per 100 years (374/537 participants, 69.6%), while treatment failure, death and default rates were 10.0 per 100 years (101 participants, 18.8%), 3.4 per 100 years (36 participants, 6.7%) and 2.7 per 100 years (26 participants, 4.8%) respectively. Independent predictors of poor treatment outcomes included age >60 years (hazard ratio (HR) 2.3, 95% confidence interval (CI) 1.2-4.2), patients registered as experiencing relapse (HR 2.2, 95% CI 1.1-4.4), patients registered as receiving treatment after failure (HR 2.4, 95% CI 1.2-4.9), use of standardized MDR-TB regimens (HR 0.6, 95% CI 0.4-1.0), cavitary disease (HR 4.9, 95% CI 2.8-8.6) and adverse events (HR 2.5, 95% CI 1.2-5.5). CONCLUSIONS: Under well-designed treatment and management scheme, high treatment success rates were achieved in a high-MDR-TB-burden country. Antimicrobial susceptibility testing for all second-line drugs should be conducted to further assist in the treatment of MDR-TB.
OBJECTIVES: To examine treatment outcomes and factors associated with poor outcome of multidrug-resistant (MDR) tuberculosis (TB) in China. METHODS: We conducted a prospective observational cohort study including consecutive patients with MDR-TB between 2009 and 2013 in six regions of Zhejiang province. Patients were prescribed treatments by infectious disease specialists, and treatment outcomes were recorded. Sociodemographic characteristics were obtained through a structured questionnaire. The primary endpoint was poor treatment outcomes, defined as treatment failure based on microbiologic persistence, default (lost to follow-up) or death at 24 months. We assessed risk factors for poor treatment outcomes using a Cox proportional hazards model. RESULTS: A total of 820 MDR-TB patients were observed, and 537 with known treatment outcomes were included in our study. Overall, the treatment success rate was 40.2 per 100 years (374/537 participants, 69.6%), while treatment failure, death and default rates were 10.0 per 100 years (101 participants, 18.8%), 3.4 per 100 years (36 participants, 6.7%) and 2.7 per 100 years (26 participants, 4.8%) respectively. Independent predictors of poor treatment outcomes included age >60 years (hazard ratio (HR) 2.3, 95% confidence interval (CI) 1.2-4.2), patients registered as experiencing relapse (HR 2.2, 95% CI 1.1-4.4), patients registered as receiving treatment after failure (HR 2.4, 95% CI 1.2-4.9), use of standardized MDR-TB regimens (HR 0.6, 95% CI 0.4-1.0), cavitary disease (HR 4.9, 95% CI 2.8-8.6) and adverse events (HR 2.5, 95% CI 1.2-5.5). CONCLUSIONS: Under well-designed treatment and management scheme, high treatment success rates were achieved in a high-MDR-TB-burden country. Antimicrobial susceptibility testing for all second-line drugs should be conducted to further assist in the treatment of MDR-TB.
Authors: Victoria Panford; Emmanuel Kumah; Collins Kokuro; Prince Owusu Adoma; Michael Afari Baidoo; Adam Fusheini; Samuel Egyakwa Ankomah; Samuel Kofi Agyei; Peter Agyei-Baffour Journal: BMJ Open Date: 2022-07-05 Impact factor: 3.006
Authors: Joseph Baruch Baluku; Bridget Nakazibwe; Joshua Naloka; Martin Nabwana; Sarah Mwanja; Rose Mulwana; Mike Sempiira; Sylvia Nassozi; Febronius Babirye; Carol Namugenyi; Samuel Ntambi; Sharon Namiiro; Felix Bongomin; Richard Katuramu; Irene Andia-Biraro; William Worodria Journal: J Clin Tuberc Other Mycobact Dis Date: 2021-01-27
Authors: Qingchun Li; Cynthia X Shi; Min Lu; Limin Wu; Yifei Wu; Meng Wang; Le Wang; Gang Zhao; Li Xie; Han-Zhu Qian Journal: Medicine (Baltimore) Date: 2020-07-24 Impact factor: 1.817